JA2-WP5 EUnetHTA Joint Action 2 (2012-15)
2015 - PDF

The purpose of the assessment is to evaluate Vorapaxar (ZONTIVITY™) for the reduction of cardiovascular events.

Final version of the assessment was published in June 2015

Below is the documentation provided by the Joint Assessment authoring team: